The FDA's compounding advisory committee will meet July 23-24 to debate whether to ease restrictions on seven injectable peptides — including BPC-157, Semax, and TB-500 — that currently thrive in a gray market fueled by social media influencers and wellness enthusiasts. The problem? Evidence of safety and efficacy in humans ranges from "thin to nonexistent." Dr. Eric Topol, director of the Scripps Research Translational Institute, was blunt: "The ban is...